DOCSLIB.ORG

ANNUAL REPORT 2018 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ANNUAL REPORT 2018 2-5-1, Nihonbashi-Honcho, Chuo-Ku, Tokyo 103-8411, Japan For the Year Ended March 31, 2018 Astellas Pharma Inc. ANNUAL REPORT 2018 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan https://www.astellas.com/en/ Please direct inquiries concerning Annual Report 2018 to: Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3202 FAX: +81-3-5201-7473 Issued in September 2018 Contents Business Philosophy Business Philosophy/Editorial Policy 2 Raison D’être CEO Message 3 Contribute toward improving the health of people around the world Corporate Strategy and through the provision of innovative and Corporate Governance 8 reliable pharmaceutical products Astellas’ Value Creation Process 9 Mission Mid-Term Strategy 11 Sustainable enhancement of Feature: Focus Area Approach 15 enterprise value CFO Message 17 CEO Message Interview with an For details, please visit the following website: CSR-Based Management 19 Outside Director Contribution to the Sustainable Development Goals 22 Web https://www.astellas.com/jp/en/ Corporate Governance 23 about/philosophy Risk Management The CEO explains the management strategy P An outside Director talks about the effectiveness P 28 for sustainable growth. 3 of the Board of Directors and other topics. 31 Directors 29 Interview with an Outside Director 31 Editorial Policy To enable deeper stakeholder understanding of Astellas’ efforts to Business Review 34 continue to create value for sustainable growth, the Company has published this annual report as an integrated report. Executive Committee 35 In this report, we have attempted to provide disclosure while Executive Messages 36 taking note of the Guiding Principles and Content Elements of the international integrated reporting framework of the International Research and Development Integrated Reporting Council (IIRC). We have also referred to GRI Standards* published by the Global Reporting Initiative and Research and Development 39 Environmental Reporting Guidelines (Fiscal Year 2012 Version) issued by Japan’s Ministry of the Environment. R&D Topics during the Year 43 In creating the report, we have sought to make an effective tool CSR Activities in Research and Development 47 for communicating with our many stakeholders. We have therefore used charts and photographs, and endeavored to use plain language that is easy to read. Manufacturing to Sales and Procurement Mid-Term Strategy/ Executive Astellas has adopted the International Financial Reporting Overview of Main Products 49 Feature: Focus Messages Standards (IFRS), effective from fiscal 2013. Information in this report is Area Approach based on IFRS unless otherwise indicated. The monetary amounts CSR Activities from Manufacturing to Sales 53 stated in this report have been rounded off to the nearest unit, and the number of shares has been rounded down to the nearest whole Improvement in the Quality and Efficiency of Operations We introduce the strategy and policies of P11 Top management explains each strategy. P36 number. Unless otherwise noted, percentage changes and other the new mid-term strategic plan. ratios involving the previous fiscal year have been rounded off to the Recent Initiatives 55 second decimal place. Our People, Our Organization 56 * For the GRI Standards Content Index, please visit the following website: https://www.astellas.com/jp/en/investors/ir-library/annual-report Ethics and Compliance 59 Cautionary Note Access to Health 63 Scope of the Report In this annual report, statements made with respect to current plans, estimates, Period covered Social Contribution 67 strategies and beliefs and other statements that are not historical facts are Fiscal 2017 (April 1, 2017 - March 31, 2018) Environmental Preservation 69 forward-looking statements about the future performance of Astellas. These * As much as possible, we have used the latest information available at the time of statements are based on management’s current assumptions and beliefs in publication. Stakeholder Engagement 73 * The period and scope of coverage may vary depending on the subject. We have light of the information currently available to it and involve known and noted each such case individually. unknown risks and uncertainties. A number of factors could cause actual results * The figures indicated in the field of Environment represent the results for fiscal 2017 (April 1, 2017 to March 31, 2018) in Japan and the calendar year 2017 (January 1 to Financial Information and Data 74 to differ materially from those discussed in the forward-looking statements. December 31, 2017) for overseas operations as a combined total. Such factors include, but are not limited to: (i) changes in general economic Organizations covered Financial Summary conditions and in laws and regulations relating to pharmaceutical markets, (ii) 75 Astellas Pharma Inc. and its consolidated subsidiaries in Japan and overseas (referred to Financial Review 77 currency exchange rate fluctuations, (iii) delays in new product launches, (iv) in the report as “Astellas”) the inability of Astellas to market existing and new products effectively, (v) the * The Americas includes North America and Latin America, and EMEA includes Europe, Consolidated Financial Statements 86 Directors the Middle East, and Africa. inability of Astellas to continue to effectively research and develop products * In the field of Environment, this report covers all the business sites in Japan and accepted by customers in highly competitive markets, and (vi) infringements of production sites overseas that are subject to the former Environmental Action Plan, and Notes to Consolidated Financial Statements 91 it covers all the business sites that are subject to the new Environmental Action Plan. Astellas’ intellectual property rights by third parties. Information about Independent Auditor’s Report 152 Note: In the information about pharmaceutical products in this report, market size, pharmaceutical products (including products currently in development) which market share and product ranking are sourced from the following data. Investor Information 153 We introduce Directors under the new is included in this annual report is not intended to constitute an advertisement Copyright © 2018 IQVIA. P29 Calculated based on IQVIA MIDAS 2018Q1 MAT Corporate Data/Principal Subsidiaries and Affiliates 154 management system. or medical advice. Reprinted with permission 1 Astellas Pharma Inc. ANNUAL REPORT 2018 Contents Business Philosophy Business Philosophy/Editorial Policy 2 Raison D’être CEO Message 3 Contribute toward improving the health of people around the world Corporate Strategy and through the provision of innovative and Corporate Governance 8 reliable pharmaceutical products Astellas’ Value Creation Process 9 Mission Mid-Term Strategy 11 Sustainable enhancement of Feature: Focus Area Approach 15 enterprise value CFO Message 17 CEO Message Interview with an For details, please visit the following website: CSR-Based Management 19 Outside Director Contribution to the Sustainable Development Goals 22 Web https://www.astellas.com/jp/en/ Corporate Governance 23 about/philosophy Risk Management The CEO explains the management strategy P An outside Director talks about the effectiveness P 28 for sustainable growth. 3 of the Board of Directors and other topics. 31 Directors 29 Interview with an Outside Director 31 Editorial Policy To enable deeper stakeholder understanding of Astellas’ efforts to Business Review 34 continue to create value for sustainable growth, the Company has published this annual report as an integrated report. Executive Committee 35 In this report, we have attempted to provide disclosure while Executive Messages 36 taking note of the Guiding Principles and Content Elements of the international integrated reporting framework of the International Research and Development Integrated Reporting Council (IIRC). We have also referred to GRI Standards* published by the Global Reporting Initiative and Research and Development 39 Environmental Reporting Guidelines (Fiscal Year 2012 Version) issued by Japan’s Ministry of the Environment. R&D Topics during the Year 43 In creating the report, we have sought to make an effective tool CSR Activities in Research and Development 47 for communicating with our many stakeholders. We have therefore used charts and photographs, and endeavored to use plain language that is easy to read. Manufacturing to Sales and Procurement Mid-Term Strategy/ Executive Astellas has adopted the International Financial Reporting Overview of Main Products 49 Feature: Focus Messages Standards (IFRS), effective from fiscal 2013. Information in this report is Area Approach based on IFRS unless otherwise indicated. The monetary amounts CSR Activities from Manufacturing to Sales 53 stated in this report have been rounded off to the nearest unit, and the number of shares has been rounded down to the nearest whole Improvement in the Quality and Efficiency of Operations We introduce the strategy and policies of P11 Top management explains each strategy. P36 number. Unless otherwise noted, percentage changes and other the new mid-term strategic plan. ratios involving the previous fiscal year have been rounded off to the Recent Initiatives 55 second decimal place. Our People, Our Organization 56 * For the GRI Standards Content Index, please visit the following website: https://www.astellas.com/jp/en/investors/ir-library/annual-report Ethics and Compliance 59 Cautionary Note Access to Health 63 Scope of the Report In this annual report, statements made with respect to current plans, estimates, Period covered Social
Load more

Recommended publications
  • View a Copy of This Licence, Visit Tivecommons.Org/Licenses/By/4.0
    Katakami et al. Cardiovasc Diabetol (2020) 19:110 https://doi.org/10.1186/s12933-020-01079-4 Cardiovascular Diabetology ORIGINAL INVESTIGATION Open Access Tofoglifozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study Naoto Katakami1,2* , Tomoya Mita3, Hidenori Yoshii4, Toshihiko Shiraiwa5, Tetsuyuki Yasuda6, Yosuke Okada7, Keiichi Torimoto7, Yutaka Umayahara8, Hideaki Kaneto9, Takeshi Osonoi10, Tsunehiko Yamamoto11, Nobuichi Kuribayashi12, Kazuhisa Maeda13, Hiroki Yokoyama14, Keisuke Kosugi15, Kentaro Ohtoshi16, Isao Hayashi17, Satoru Sumitani18, Mamiko Tsugawa19, Kayoko Ryomoto20, Hideki Taki21, Tadashi Nakamura22, Satoshi Kawashima23, Yasunori Sato24, Hirotaka Watada3 and Iichiro Shimomura1 on behalf of the UTOPIA study investigators Abstract Background: This study aimed to investigate the preventive efects of tofoglifozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD) by monitoring carotid intima-media thickness (IMT). Methods: This prospective, randomized, open-label, blinded-endpoint, multicenter, parallel-group, comparative study included 340 subjects with T2DM and no history of apparent CVD recruited at 24 clinical units. Subjects were randomly allocated to either the tofoglifozin treatment group (n 169) or conventional treatment group using drugs other than SGLT2 inhibitors (n 171). Primary outcomes were changes= in mean and maximum common carotid IMT measured by echography during= a 104-week treatment period. Results: In a mixed-efects model for repeated measures, the mean IMT of the common carotid artery (mean- IMT-CCA), along with the right and left maximum IMT of the CCA (max-IMT-CCA), signifcantly declined in both the tofoglifozin ( 0.132 mm, SE 0.007; 0.163 mm, SE 0.013; 0.170 mm, SE 0.020, respectively) and the control group ( 0.140 mm,− SE 0.006; 0.190 mm,− SE 0.012; 0.190 mm,− SE 0.020, respectively).
    [Show full text]
  • Broadband Coverage 97% Fixed and Mobile Broadband
    Connectivity Broadband market developments in the EU Digital Economy and Society Index Report 2019 Connectivity The Digital Economy and Society Index (DESI) is a composite index that summarises relevant indicators on Europe’s digital performance and tracks the progress of EU Member States in digital competitiveness. The five dimensions of the DESI 1 Connectivity Fixed broadband, mobile broadband, fast and ultrafast Finland, Sweden, the Netherlands and Denmark, have the most broadband and prices advanced digital economies in the EU followed by the UK, 2 Human capital Internet user skills and advanced skills Luxembourg, Ireland and Estonia. 3 Use of internet Citizens' use of internet services and online transactions Bulgaria, Romania, Greece and Poland have the lowest scores on the index. 4 Integration of Business digitisation and e-commerce digital technology 5 Digital public e-Government and e-health services Digital Economy and Society Index (DESI) 2019 80 1 Connectivity 2 Human capital 3 Use of internet services 4 Integration of digital technology 5 Digital public services 70 60 50 40 30 20 10 0 FI SE NL DK UK LU IE EE BE MT ES DE AT EU LT FR SI LV CZ PT HR SK CY HU IT PL EL RO BG Source: DESI 2019, European Commission DESI Report 2019 – Connectivity 2 In Connectivity, Denmark had the highest score, followed by Luxembourg, the Netherlands, Sweden and Finland. Greece, Croatia and Lithuania had the weakest performance in this dimension of the DESI. Connectivity indicators in DESI 2019 EU The connectivity dimension looks at both the demand and the supply side of 1a1 Fixed broadband coverage 97% fixed and mobile broadband.
    [Show full text]
  • OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration
    OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration July 21, 2009 9:24 PM ET MELVILLE, NY and CAMBRIDGE, Mass., July 21, 2009 – OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) and AVEO Pharmaceuticals, Inc. today announced that they have expanded the drug discovery and translational research collaboration announced in October of 2007. The alliance is anchored around developing molecular targeted therapies to target the underlying mechanisms of epithelial-mesenchymal transition (EMT) in cancer and to develop proprietary datasets of associated patient selection biomarkers to support OSI’s targeted medicine pipeline. EMT is a process of emerging significance in tumor development and disease progression and the focal point of OSI’s proprietary oncology research efforts. The companies are expanding their efforts to validate cancer targets and to deploy key elements of AVEO’s proprietary translational research platform in support of OSI’s clinical development programs. Under the terms of the expanded discovery and research agreement, OSI will pay AVEO a total of $20 million at closing, $5 million of which is an upfront cash payment and $15 million of which is the purchase of additional equity in AVEO. OSI will also provide AVEO research funding over the next two years to support the collaboration, and the potential to achieve additional royalties and milestones. In return, OSI will immediately receive rights beyond the original collaboration including rights to additional EMT targets (including up to 4 antibody targets) and increased access to AVEO technology (i.e. tumor models, archives and biomarkers). OSI is also acquiring non-exclusive access to AVEO’s proprietary bioinformatics platform.
    [Show full text]
  • IPR2016-01284 Patent 6,900,221 B1 ______
    [email protected] Paper No. 49 571.272.7822 Filed: January 8, 2018 UNITED STATES PATENT AND TRADEMARK OFFICE ____________________ BEFORE THE PATENT TRIAL AND APPEAL BOARD ____________________ APOTEX INC., APOTEX CORP., APOTEX PHARMACEUTICALS HOLDINGS INC., AND APOTEX HOLDINGS, INC., Petitioner, v. OSI PHARMACEUTICALS LLC, Patent Owner. ____________________ Case IPR2016-01284 Patent 6,900,221 B1 ____________ Before LORA M. GREEN, RAMA G. ELLURU, and ZHENYU YANG, Administrative Patent Judges. GREEN, Administrative Patent Judge. FINAL WRITTEN DECISION Determining That Claims 44‒46 and 53 Are Shown to Be Unpatentable 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73 IPR2016-01284 Patent 6,900,221 B1 I. INTRODUCTION Apotex Inc., Apotex Corp., Apotex Pharmaceuticals Holdings Inc., and Apotex Holdings, Inc., (“Apotex” or “Petitioner”) filed a Petition requesting an inter partes review of claims 44–47 and 53 of U.S. Patent No. 6,900,221 B1 (Ex. 1001, “the ’221 patent”). Paper 3 (“Pet.”). OSI Pharmaceuticals LLC1 (“OSI” or “Patent Owner”) filed a Preliminary Response to the Petition.2 Paper 7 (“Prelim. Resp.”). We determined that the information presented in the Petition and the Preliminary Response demonstrated that there was a reasonable likelihood that Petitioner would prevail in challenging claims 44–47 and 53 as unpatentable under 35 U.S.C. § 103(a). Pursuant to 35 U.S.C. § 314, we instituted trial on January 9, 2017, as to all of the challenged claims of the ’221 patent. Paper 8 (“Institution Decision” or “Dec. Inst.”). On February 8, 2017, the parties filed a Joint Motion to Limit Petition Under 37 C.F.R.
    [Show full text]
  • Every Avenue Available Lessons from Monetary History for Tackling Climate Change
    EVERY AVENUE AVAILABLE LESSONS FROM MONETARY HISTORY FOR TACKLING CLIMATE CHANGE Rens van Tilburg and Aleksandar Simić February 2021 Every Avenue Available “I WANT TO EXPLORE EVERY AVENUE AVAILABLE 2 IN ORDER TO COMBAT CLIMATE CHANGE” Christine Lagarde, president of the European Central Bank, July 2020 Sustainable Finance Lab Every Avenue Available 3 Utrecht, February 2021. The Sustainable Finance Lab (SFL https://sustainablefinancelab.nl/en) is an academic think tank whose members are mostly professors from different universities in the Netherlands. The aim of the SFL is a stable and robust financial sector that contributes to an economy that serves humanity without depleting its environment. To this end the SFL develops ideas and provides a platform to discuss them, thus bridging science and practice. This paper has been drafted by Rens van Tilburg, Director of the Sustainable Finance Lab at Utrecht University ([email protected]) and Aleksandar Simić, researcher of the SFL. The authors wish to thank Roben Kloosterman for his excellent research support and Alexander Barkawi, Simon Dikau, Maarten Kavelaars, Jens van ‘t Klooster, Cormac Petit, Rick van der Ploeg, Dirk Schoenmaker and Roland Uittenbogaard Sustainable Finance Lab for their comments. The views expressed in this publication are those of the authors and do not necessarily reflect those of all members of the Sustainable Finance Lab. This paper was commissioned by the Council on Economic Policies and supported by the European Climate Foundation. Every Avenue Available KEY TAKEAWAYS Insufficient action to limit climate change The costs of runaway climate change are much higher than those of limiting it.
    [Show full text]
  • Ranking of Stocks by Market Capitalization(As of End of Mar.2020)
    Ranking of Stocks by Market Capitalization(As of End of Mar.2020) 1st Section Rank Code Issue Market Capitalization \100mil. 1 7203 TOYOTA MOTOR CORPORATION 212,127 2 9437 NTT DOCOMO,INC. 112,630 3 6861 KEYENCE CORPORATION 84,709 4 6758 SONY CORPORATION 81,786 5 9984 SoftBank Group Corp. 79,162 6 9433 KDDI CORPORATION 75,136 7 4519 CHUGAI PHARMACEUTICAL CO.,LTD. 69,960 8 9432 NIPPON TELEGRAPH AND TELEPHONE CORPORATION 68,006 9 9434 SoftBank Corp. 65,799 10 7974 Nintendo Co.,Ltd. 54,787 11 8306 Mitsubishi UFJ Financial Group,Inc. 54,735 12 4568 DAIICHI SANKYO COMPANY,LIMITED 52,707 13 4502 Takeda Pharmaceutical Company Limited 52,146 14 4661 ORIENTAL LAND CO.,LTD. 50,261 15 6098 Recruit Holdings Co.,Ltd. 47,419 16 9983 FAST RETAILING CO.,LTD. 46,873 17 7182 JAPAN POST BANK Co.,Ltd. 44,865 18 4063 Shin-Etsu Chemical Co.,Ltd. 44,707 19 7267 HONDA MOTOR CO.,LTD. 44,017 20 4452 Kao Corporation 42,560 21 6367 DAIKIN INDUSTRIES,LTD. 38,603 22 6981 Murata Manufacturing Co.,Ltd. 36,980 23 8058 Mitsubishi Corporation 36,436 24 8316 Sumitomo Mitsui Financial Group,Inc. 36,018 25 9022 Central Japan Railway Company 35,679 26 8001 ITOCHU Corporation 35,541 27 8766 Tokio Marine Holdings,Inc. 35,145 28 7741 HOYA CORPORATION 34,808 29 6594 NIDEC CORPORATION 33,433 30 8035 Tokyo Electron Limited 32,000 31 3382 Seven & I Holdings Co.,Ltd. 31,699 32 7751 CANON INC. 31,463 33 8411 Mizuho Financial Group,Inc.
    [Show full text]
  • Press Release
    Press Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Sunao Manabe, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Junichi Onuma, Vice President, Corporate Communications Department Telephone: +81-3-6225-1126 https://www.daiichisankyo.com Daiichi Sankyo Announces Transfer from Astellas Pharma of Three Products in Asia Tokyo, Japan (October 15, 2019) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it agreed with Astellas Pharma Inc. (hereafter, Astellas Pharma) that Astellas Pharma local subsidiaries companies in six Asian countries will transfer three products to Daiichi Sankyo. The products to be transferred and the countries where they are sold are as follows. Product Korea China Taiwan Thailand Philippines Indonesia [generic name (brand name)] Ramosetron Antiemetic ○ ○ ○ ○ (Nasea) Nicardipine Anti- ○ ○ ○ (Perdipine) hypertensive Barnidipine Anti- ○ (Oldeca) hypertensive ○ indicate the countries where the products are sold The antiemetics are expected to have synergistic effects with mirogabalin and the cancer drugs that Daiichi Sankyo is currently developing in Asia, and the two antihypertensives are expected to effectively utilize Daiichi Sankyo’s current infrastructures in combination with its cardiovascular products, such as olmesartan and edoxaban. The total net sales of Astellas Pharma's three products in fiscal year 2018 were approximately 5.0 billion yen. 1 Daiichi Sankyo will take over the rights
    [Show full text]
  • In the United States District Court for the District of Delaware
    Case 1:15-cv-01063-UNA Document 1 Filed 11/17/15 Page 1 of 17 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE OSI PHARMACEUTICALS, LLC, PFIZER ) INC., and GENENTECH, INC., ) ) Plaintiffs, ) ) v. ) C.A. No. ) BRECKENRIDGE PHARMACEUTICAL, ) INC. and NATCO PHARMA LTD., ) ) Defendants. ) COMPLAINT FOR PATENT INFRINGEMENT Plaintiffs OSI Pharmaceuticals, LLC (“OSI”), Pfizer Inc. (“Pfizer”) and Genentech, Inc. (“Genentech”) (collectively, “Plaintiffs”), by their undersigned attorneys, bring this action against Defendant Breckenridge Pharmaceutical Inc., (“Breckenridge”), and Natco Pharma Ltd. (“Natco”) (collectively, “Breckenridge/Natco”) for patent infringement and allege as follows: NATURE OF THE ACTION 1. This is an action for patent infringement under the patent laws of the United States, Title 35 of the United States Code, the Federal Food, Drug, and Cosmetic Act, Title 21 of the United States Code, and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 et seq., arising from Breckenridge/Natco’s filing of an Abbreviated New Drug Application No. 208488 (“Breckenridge/Natco ANDA” or “ANDA No. 208488”) with the United States Food and Drug Administration (“FDA”) seeking approval to commercially market generic versions of TARCEVA® (“Breckenridge/Natco’s Proposed Generic Products”) prior to the expiration of certain patents that relate to that product, United States Reissued Patent No. RE 41,065 (“the RE ‘065 patent”), and United States Patent No. 6,900,221 (“the ‘221 patent”). Case 1:15-cv-01063-UNA Document 1 Filed 11/17/15 Page 2 of 17 PageID #: 2 THE PARTIES 2. Plaintiff OSI is a limited liability company organized and existing under the laws of the State of Delaware, with a principal place of business at 1 Astellas Way, Northbrook, IL 60062.
    [Show full text]
  • The Knowns and Unknowns of West Nile Virus in Europe: What Did We Learn from the 2018 Outbreak?
    Expert Review of Anti-infective Therapy ISSN: 1478-7210 (Print) 1744-8336 (Online) Journal homepage: https://www.tandfonline.com/loi/ierz20 The knowns and unknowns of West Nile virus in Europe: what did we learn from the 2018 outbreak? Jeremy V Camp & Norbert Nowotny To cite this article: Jeremy V Camp & Norbert Nowotny (2020): The knowns and unknowns of West Nile virus in Europe: what did we learn from the 2018 outbreak?, Expert Review of Anti- infective Therapy, DOI: 10.1080/14787210.2020.1713751 To link to this article: https://doi.org/10.1080/14787210.2020.1713751 Accepted author version posted online: 08 Jan 2020. Published online: 14 Jan 2020. Submit your article to this journal Article views: 11 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ierz20 EXPERT REVIEW OF ANTI-INFECTIVE THERAPY https://doi.org/10.1080/14787210.2020.1713751 REVIEW The knowns and unknowns of West Nile virus in Europe: what did we learn from the 2018 outbreak? Jeremy V Camp a and Norbert Nowotny a,b aViral Zoonoses, Emerging and Vector-Borne Infections Group, Institute of Virology, University of Veterinary Medicine Vienna, Vienna, Austria; bDepartment of Basic Medical Sciences, College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, United Arab Emirates ABSTRACT ARTICLE HISTORY Introduction: West Nile virus (WNV) is a mosquito-borne human and animal pathogen with nearly Received 28 October 2019 worldwide distribution. In Europe, the virus is endemic with seasonal regional outbreaks that have Accepted 7 January 2020 increased in frequency over the last 10 years.
    [Show full text]
  • 17TH ANNUAL PHARMACEUTICAL and MEDICAL DEVICE COMPLIANCE CONGRESS Office of Inspector General Update
    17TH ANNUAL PHARMACEUTICAL AND MEDICAL DEVICE COMPLIANCE CONGRESS Office of Inspector General Update Mary E. Riordan, Senior Counsel Office of Counsel to the Inspector General October 19, 2016 AGENDA FOR TODAY Update on recent enforcement activity Update on OIG reports and other publications Lessons/suggestions for consideration ISSUES IN RECENT SETTLEMENTS Settlements addressed a variety of areas: Kickback issues Marketing and sales issues Medicaid drug rebate program issues Drug price reporting issues FALSE CLAIM ACT SETTLEMENTS Kickback-related settlements Salix Pharmaceuticals, Inc. Olympus Corporation of the Americas Novartis Pharmaceuticals Warner Chilcott Omnicare, Inc. FALSE CLAIM ACT SETTLEMENTS Settlements involving sales and marketing issues Acclarent, Inc. Genentech Inc. and OSI Pharmaceuticals LLC Paradigm Spine Qualitest Pharmaceuticals Settlement involving Medicaid drug rebate issues Wyeth/Pfizer Settlements involving other issues Imported and compounded drugs CIVIL MONETARY PENALTY SETTLEMENTS Drug Price Reporting CMP Settlements Nephron Pharmaceuticals Corporation Cipher Pharmaceuticals US, LLC Coloplast Corp. OIG REPORTS Drug pricing issues “Average Manufacturer Prices Increased Faster Than Inflation for Many Generic Drugs” – December 2015 (A-06-15-00030) 340B program issues “Part B Payment for 340B Purchased Drugs” - Nov. 2015 (OEI-12-14-00030) “State Efforts to Exclude 340B drugs from Medicaid Managed Care Rebates” – June 2016 (OEI-05-14- 00430) OIG REPORTS Reports relating to the Medicaid
    [Show full text]
  • R&Co Risk-Based International Index – Weighting
    Rothschild & Co Risk-Based International Index Indicative Index Weight Data as of June 30, 2021 on close Constituent Exchange Country Index Weight(%) Jardine Matheson Holdings Ltd Singapore 1.46 LEG Immobilien SE Germany 0.98 Ajinomoto Co Inc Japan 0.95 SoftBank Corp Japan 0.89 Shimano Inc Japan 0.85 FUJIFILM Holdings Corp Japan 0.73 Singapore Exchange Ltd Singapore 0.72 Japan Tobacco Inc Japan 0.72 Cellnex Telecom SA Spain 0.69 Nintendo Co Ltd Japan 0.69 Carrefour SA France 0.67 Nexon Co Ltd Japan 0.66 Deutsche Wohnen SE Germany 0.65 Bank of China Ltd Hong Kong 0.64 REN - Redes Energeticas Nacion Portugal 0.63 Pan Pacific International Hold Japan 0.63 Japan Post Holdings Co Ltd Japan 0.62 Nippon Telegraph & Telephone C Japan 0.61 Roche Holding AG Switzerland 0.61 Nestle SA Switzerland 0.61 Novo Nordisk A/S Denmark 0.59 ENEOS Holdings Inc Japan 0.59 Nomura Research Institute Ltd Japan 0.59 Koninklijke Ahold Delhaize NV Netherlands 0.59 Jeronimo Martins SGPS SA Portugal 0.58 HelloFresh SE Germany 0.58 Toshiba Corp Japan 0.58 Hoya Corp Japan 0.58 Siemens Healthineers AG Germany 0.58 MS&AD Insurance Group Holdings Japan 0.57 Coloplast A/S Denmark 0.57 Kerry Group PLC Ireland 0.57 Scout24 AG Germany 0.57 SG Holdings Co Ltd Japan 0.56 Symrise AG Germany 0.56 Nitori Holdings Co Ltd Japan 0.56 Beiersdorf AG Germany 0.55 Mitsubishi Corp Japan 0.55 KDDI Corp Japan 0.55 Sysmex Corp Japan 0.55 Chr Hansen Holding A/S Denmark 0.55 Ping An Insurance Group Co of Hong Kong 0.55 Eisai Co Ltd Japan 0.54 Chocoladefabriken Lindt & Spru Switzerland 0.54 Givaudan
    [Show full text]
  • Association Between Variability in Body Mass Index and Development of Type 2 Diabetes: Panasonic Cohort Study
    Epidemiology/Health services research Open access Original research BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2021-002123 on 22 April 2021. Downloaded from Association between variability in body mass index and development of type 2 diabetes: Panasonic cohort study Hiroshi Okada ,1 Masahide Hamaguchi ,2 Momoko Habu,1 Kazushiro Kurogi,3 Hiroaki Murata,4 Masato Ito,3 Michiaki Fukui2 To cite: Okada H, ABSTRACT Hamaguchi M, Habu M, Introduction Contrasting results have been reported for Significance of this study et al. Association between the association between the variability in body weight variability in body mass index and development of diabetes. In the present study, we What is already known about this subject? and development of type 2 evaluated the association between the variability in body ► Obesity or body weight gain accelerate the develop- diabetes: Panasonic cohort ment of diabetes. study. BMJ Open Diab Res Care mass index (BMI) and development of type 2 diabetes in 19 412 Japanese participants without obesity and without ► The association between the variability in body 2021;9:e002123. doi:10.1136/ weight and development of diabetes is controversial. bmjdrc-2021-002123 body weight gain or loss during the study period. Research design and methods We recorded body weight What are the new findings? of the participants consecutively each year in Panasonic ► The risk for developing diabetes increased by 11.1% Received 9 January 2021 Corporation, Osaka, Japan from 2008 to 2014 to evaluate Revised 26 February 2021 per 1% increase in coefficient of variation of body the variability of BMI. The participants with obesity (BMI mass index (BMI).
    [Show full text]